Table 7: Overview of Treatment-emergent Adverse Events; All Treated Analysis Set(原safety表table1)
Any TEAE||Total||123 (99.2%)----An overview of TEAEs by treatment received during the study is presented in Table 1.All but 1 subject had 1 or more reported TEAE (99%).
原模板:
&row_1_1; overview of &row_1_1; by treatment received during the study is presented in Table 1.All but 1 subject had 1 or more reported &row_1_1; ( &data_1_%; ) .----Any TEAE||Total||123 (99.2%)----An overview of TEAEs by treatment received during the study is presented in Table 1.All but 1 subject had 1 or more reported TEAE (99%).
扩展:
无


Table 6: Time to Disease Progression based on IRC Assessment; All Treated Analysis Set (Study 54767414MMY2002)(原efficy表table4)
Time to disease progression|Number of events (%)||16 mg/kg||73 (68.9%)----In the 16 mg/kg group, 69% of subjects had experienced disease progression at the time of the primary analysis.
原模板：
In the &column_1_1; group, &data_1_%; &row_1_1; subjects had experienced &row_1_1; the &row_1_1; the primary analysis.----Time to disease progression|Number of events (%)||16 mg/kg||73 (68.9%)----In the 16 mg/kg group, 69% of subjects had experienced disease progression at the time of the primary analysis.
扩展：
无

Kaplan-Meier estimate (months)|Median (95% CI)||16 mg/kg||3.71 (2.79, 5.39)----The median time to progression was 3.7 months.
原模板：
The &row_1_2; time to progression was 3.7 &row_1_1;----Kaplan-Meier estimate (months)|Median (95% CI)||16 mg/kg||3.71 (2.79, 5.39)----The median time to progression was 3.7 months.
扩展：
无

Table5:Duration of Response based on IRC Assessment; Responders in All Treated Analysis Set (Study 54767414MMY2002)(原efficy表table2)
无一个三元组的
